Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m(2)) improved overall survival in adults <60 years old with acute myel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood
Hauptverfasser: Luskin, Marlise R., Lee, Ju-Whei, Fernandez, Hugo F., Abdel-Wahab, Omar, Bennett, John M., Ketterling, Rhett P., Lazarus, Hillard M., Levine, Ross L., Litzow, Mark R., Paietta, Elisabeth M., Patel, Jay P., Racevskis, Janis, Rowe, Jacob M., Tallman, Martin S., Sun, Zhuoxin, Luger, Selina M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Hematology 2016
Schlagworte:
Clinical Trials and Observations
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4807422/
https://ncbi.nlm.nih.gov/pubmed/26755712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-07-657403
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge